BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 1412120)

  • 1. Nilutamide pneumonitis: a report on eight patients.
    Pfitzenmeyer P; Foucher P; Piard F; Coudert B; Braud ML; Gabez P; Lacroix S; Mabille JP; Camus P
    Thorax; 1992 Aug; 47(8):622-7. PubMed ID: 1412120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Provocation test coupled with bronchoalveolar lavage in diagnosis of drug (nilutamide)-induced hypersensitivity pneumonitis.
    Akoun GM; Liote HA; Liote F; Gauthier-Rahman S; Kuntz D
    Chest; 1990 Feb; 97(2):495-8. PubMed ID: 2298082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous liver and lung toxicity related to the nonsteroidal antiandrogen nilutamide (Anandron): a case report.
    Gomez JL; Dupont A; Cusan L; Tremblay M; Tremblay M; Labrie F
    Am J Med; 1992 May; 92(5):563-6. PubMed ID: 1580304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails.
    Kassouf W; Tanguay S; Aprikian AG
    J Urol; 2003 May; 169(5):1742-4. PubMed ID: 12686822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial.
    Janknegt RA; Abbou CC; Bartoletti R; Bernstein-Hahn L; Bracken B; Brisset JM; Da Silva FC; Chisholm G; Crawford ED; Debruyne FM
    J Urol; 1993 Jan; 149(1):77-82; discussion 83. PubMed ID: 7678043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.
    Harris MG; Coleman SG; Faulds D; Chrisp P
    Drugs Aging; 1993; 3(1):9-25. PubMed ID: 8453188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Respiratory side-effects of drugs].
    van der Drift MA; Kaajan JP
    Ned Tijdschr Geneeskd; 2002 Jan; 146(4):145-50. PubMed ID: 11845561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer.
    Nakabayashi M; Regan MM; Lifsey D; Kantoff PW; Taplin ME; Sartor O; Oh WK
    BJU Int; 2005 Oct; 96(6):783-6. PubMed ID: 16153200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary complications of hormone treatment in prostate carcinoma.
    Seigneur J; Trechot PF; Hubert J; Lamy P
    Chest; 1988 May; 93(5):1106. PubMed ID: 3129240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pulmonary toxicity of nilutamide (Anandron). Cooperative evaluation of French Regional Pharmacovigilance Centers].
    Jonville AP; Diot E; Dutertre JP; Autret E
    Therapie; 1992; 47(5):393-7. PubMed ID: 1299978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nilutamide: an antiandrogen for the treatment of prostate cancer.
    Dole EJ; Holdsworth MT
    Ann Pharmacother; 1997 Jan; 31(1):65-75. PubMed ID: 8997470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma.
    BĂ©land G; Elhilali M; Fradet Y; Laroche B; Ramsey EW; Trachtenberg J; Venner PM; Tewari HD
    Cancer; 1990 Sep; 66(5 Suppl):1074-9. PubMed ID: 2203517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide).
    Kuhn JM; Billebaud T; Navratil H; Moulonguet A; Fiet J; Grise P; Louis JF; Costa P; Husson JM; Dahan R
    N Engl J Med; 1989 Aug; 321(7):413-8. PubMed ID: 2503723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project.
    Decensi AU; Boccardo F; Guarneri D; Positano N; Paoletti MC; Costantini M; Martorana G; Giuliani L
    J Urol; 1991 Aug; 146(2):377-81. PubMed ID: 1856935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nilutamide-induced neutropenia.
    Eaton VS; Blackmore TK
    BJU Int; 2001 Nov; 88(7):801-2. PubMed ID: 11890258
    [No Abstract]   [Full Text] [Related]  

  • 16. A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.
    Davis NB; Ryan CW; Stadler WM; Vogelzang NJ
    BJU Int; 2005 Oct; 96(6):787-90. PubMed ID: 16153201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and metabolism of nilutamide.
    Creaven PJ; Pendyala L; Tremblay D
    Urology; 1991; 37(2 Suppl):13-9. PubMed ID: 1992598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Fatal fulminating hepatitis induced by nilutamide].
    Edouard A; Robinel R; Rat C; Lombard F; Lorinet C; Escarmant P
    Gastroenterol Clin Biol; 2003 Dec; 27(12):1170-1. PubMed ID: 14770126
    [No Abstract]   [Full Text] [Related]  

  • 19. [Nilutamide-induced acute hepatitis].
    Hammel P; Ducreux M; Bismuth E; Ladouch-Badre A; Benoit G; Buffet C; Etienne JP
    Gastroenterol Clin Biol; 1991; 15(6-7):557. PubMed ID: 1916139
    [No Abstract]   [Full Text] [Related]  

  • 20. [Acute depressive syndrome possibly due to nilutamide (Anandron) treatment].
    Maroy B; Pitrou P
    Therapie; 1997; 52(1):79-81. PubMed ID: 9183930
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.